Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 9/20 | 0.48 |
| ▸ | JUN | P05412 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936681 | 0.96 | SCD (0.49) | SCDJUNNFKB1NFKB2RELA | |
| SCHEMBL937626 | 0.95 | SCD (0.45) | SCDJUNNFKB1NFKB2RELA | |
| SCHEMBL937257 | 0.92 | SCD (0.52) | SCDJUNNFKB1NFKB2RELA | |
| SCHEMBL936546 | 0.86 | SCD (0.47) | SCDJUNNFKB1NFKB2RELA | |
| SCHEMBL938902 | 0.82 | NAMPT (0.47) | JUNNFKB1NFKB2RELA | |
| SCHEMBL938839 | 0.81 | ALPL (0.46) | JUNNFKB1NFKB2RELAMAOB | |
| SCHEMBL8310344 | 0.79 | JUN (0.48) | JUNNFKB1NFKB2RELAMAOB | |
| SCHEMBL937430 | 0.78 | NAAA (0.50) | SCD | |
| SCHEMBL937478 | 0.77 | NAAA (0.52) | SCD | |
| SCHEMBL938874 | 0.77 | NAAA (0.52) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964591-B2 | Pyridazine derivatives and their use as therapeutic agents | NOVARTIS PHARMA AG (CH) | 2011-06-21 | — | — | US | disclosed |
| US-7951805-B2 | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase | XENON PHARMACEUTICALS INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| EP-2316827-A1 | Piperazine derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | PRXL2A, CUTA, MC1R | SCD 52/4885JUN 4366/4885NFKB1 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.